Cytomegalovirus infection in patients with rheumatic disorders under rituximab treatment: a scoping review

This publication has 66 references indexed in Scilit:

• Infection risk in autoimmune hematological disorders with low‐dose rituximab treatment
  Journal of Clinical Laboratory Analysis, 2020
• Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
  JAMA Neurology, 2020
• Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases
  Arthritis & Rheumatology, 2019
• Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta‐analysis
  Reviews in Medical Virology, 2019
• Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia
  JAMA Network Open, 2018
• Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab
  Annals of Hematology, 2016
• Low‐ Versus High‐Dose Rituximab for Rheumatoid Arthritis: A Systematic Review and Meta‐Analysis
  Arthritis Care & Research, 2014
• High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy
  Journal of Medical Virology, 2013
• The potential role of pre‐transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: A study from the Rome Transplant Network
  American Journal of Hematology, 2011
• Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation
  Annals of Hematology, 2007